<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356705</url>
  </required_header>
  <id_info>
    <org_study_id>1098</org_study_id>
    <nct_id>NCT02356705</nct_id>
  </id_info>
  <brief_title>Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2</brief_title>
  <official_title>Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Victory, RN, CCRC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bassett Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Midazolam is often given before surgery to sedate a patient before anesthesia is given.&#xD;
      Children are often given a small dose either by mouth or squirted into the nose. Children&#xD;
      will often spit out the oral midazolam, making it difficult to know how much medicine, if&#xD;
      any, they have received. Giving midazolam into the nose is more reliable, but children may&#xD;
      complain of pain, stinging, and may become upset due to the discomfort. Nosebleeds may also&#xD;
      occur when midazolam is squirted alone into the nose. The purpose of this study is to see if&#xD;
      adding a numbing medicine, xylocaine, to the nasal midazolam makes giving the midazolam&#xD;
      easier and more comfortable without affecting how the midazolam works as a sedative. This is&#xD;
      follow up to the pilot study, Project # 994. This will expand the previous study, with&#xD;
      additional participants and revised xylocaine concentration&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pediatric Pre-Induction Anesthesia Scale at Time of Mask Placement</measure>
    <time_frame>25 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pediatric Pre-Induction Anesthesia Scale at Arrival to Operating Room</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to Discharge</measure>
    <time_frame>approximately 3 hours</time_frame>
    <description>The time (in minutes) from release from the operating room to discharge home</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Nosebleeds From Time of Drug Administration to Discharge Home</measure>
    <time_frame>approximately 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Observational Distress Score at 1 Minute (RN)</measure>
    <time_frame>1 minute</time_frame>
    <description>Visual analog scale measured from 0cm (no distress) to 10cm (high level of distress).</description>
  </other_outcome>
  <other_outcome>
    <measure>Observational Distress Score 5 Min (RN)</measure>
    <time_frame>5minutes</time_frame>
    <description>Visual analog scale measured from 0cm (no distress) to 10cm (high level of distress).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control patients will receive intranasal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Midazolam Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 0.2 mg/kg of intranasal midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam Plus Xylocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>midazolam 0.2 mg/kg given intranasally</description>
    <arm_group_label>Midazolam Plus Xylocaine</arm_group_label>
    <arm_group_label>Nasal Midazolam Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xylocaine</intervention_name>
    <description>intransal xylocaine given in conjunction with intranasal midazolam</description>
    <arm_group_label>Midazolam Plus Xylocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline placebo</intervention_name>
    <description>intranasal saline given as placebo</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children aged 18 months-7 years, scheduled for a minor Ear/Nose/Throat surgical&#xD;
             procedure requiring mask anesthesia&#xD;
&#xD;
          2. American Society of Anesthesiologists (ASA) Class 1 or 2&#xD;
&#xD;
          3. Parent willing and able to provide written informed consent&#xD;
&#xD;
          4. Parent willing and able to complete the Observed Behavioral Distress (OBD) Visual&#xD;
             Assessment Scale (VAS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ASA Class 3 or greater&#xD;
&#xD;
          2. History of allergy to midazolam or xylocaine&#xD;
&#xD;
          3. Presence of acute respiratory infection at time of surgery&#xD;
&#xD;
          4. Parent unwilling or unable to provide informed consent&#xD;
&#xD;
          5. Parent unwilling or unable to complete the OBD VAS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>david Ullman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bassett Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bassett Healthcare Network</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2015</study_first_posted>
  <results_first_submitted>February 8, 2021</results_first_submitted>
  <results_first_submitted_qc>February 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2021</results_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bassett Healthcare</investigator_affiliation>
    <investigator_full_name>Jennifer Victory, RN, CCRC</investigator_full_name>
    <investigator_title>Clinical Research Nurse Supervisor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 5, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02356705/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline Placebo</title>
          <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
        </group>
        <group group_id="P2">
          <title>Nasal Midazolam Only</title>
          <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
        </group>
        <group group_id="P3">
          <title>Midazolam Plus Xylocaine</title>
          <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline Placebo</title>
          <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
        </group>
        <group group_id="B2">
          <title>Nasal Midazolam Only</title>
          <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
        </group>
        <group group_id="B3">
          <title>Midazolam Plus Xylocaine</title>
          <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="1.7"/>
                    <measurement group_id="B2" value="3.1" spread="1.5"/>
                    <measurement group_id="B3" value="2.5" spread="1.7"/>
                    <measurement group_id="B4" value="2.7" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pediatric Pre-Induction Anesthesia Scale at Time of Mask Placement</title>
        <time_frame>25 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
          </group>
        </group_list>
        <measure>
          <title>Pediatric Pre-Induction Anesthesia Scale at Time of Mask Placement</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Agitated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alert</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Calm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Drowsy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asleep</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pediatric Pre-Induction Anesthesia Scale at Arrival to Operating Room</title>
        <time_frame>20 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
          </group>
        </group_list>
        <measure>
          <title>Pediatric Pre-Induction Anesthesia Scale at Arrival to Operating Room</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Agitated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alert</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Calm</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Drowsy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asleep</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Discharge</title>
        <description>The time (in minutes) from release from the operating room to discharge home</description>
        <time_frame>approximately 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge</title>
          <description>The time (in minutes) from release from the operating room to discharge home</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="29" upper_limit="44"/>
                    <measurement group_id="O2" value="39.5" lower_limit="22" upper_limit="50"/>
                    <measurement group_id="O3" value="35.5" lower_limit="31" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Nosebleeds From Time of Drug Administration to Discharge Home</title>
        <time_frame>approximately 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nosebleeds From Time of Drug Administration to Discharge Home</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Observational Distress Score at 1 Minute (RN)</title>
        <description>Visual analog scale measured from 0cm (no distress) to 10cm (high level of distress).</description>
        <time_frame>1 minute</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
          </group>
        </group_list>
        <measure>
          <title>Observational Distress Score at 1 Minute (RN)</title>
          <description>Visual analog scale measured from 0cm (no distress) to 10cm (high level of distress).</description>
          <units>cm VAS</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="0.6"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.01" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Observational Distress Score 5 Min (RN)</title>
        <description>Visual analog scale measured from 0cm (no distress) to 10cm (high level of distress).</description>
        <time_frame>5minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline Placebo</title>
            <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
          </group>
          <group group_id="O2">
            <title>Nasal Midazolam Only</title>
            <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
          </group>
          <group group_id="O3">
            <title>Midazolam Plus Xylocaine</title>
            <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
          </group>
        </group_list>
        <measure>
          <title>Observational Distress Score 5 Min (RN)</title>
          <description>Visual analog scale measured from 0cm (no distress) to 10cm (high level of distress).</description>
          <units>cm VAS</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During patient recovery - from time of entry into the recovery room until discharge (~3 hours)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Saline Placebo</title>
          <description>Control patients will receive intranasal saline&#xD;
saline placebo: intranasal saline given as placebo</description>
        </group>
        <group group_id="E2">
          <title>Nasal Midazolam Only</title>
          <description>Patients will receive 0.2 mg/kg of intranasal midazolam&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally</description>
        </group>
        <group group_id="E3">
          <title>Midazolam Plus Xylocaine</title>
          <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.&#xD;
Midazolam: midazolam 0.2 mg/kg given intranasally&#xD;
xylocaine: intransal xylocaine given in conjunction with intranasal midazolam</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Ullman</name_or_title>
      <organization>Bassett Healthcare</organization>
      <phone>585-750-7510</phone>
      <email>doccfi@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

